IMPACT BIOMEDICAL INC.(IBO)— Stock Profile, AI Score & Financials

Healthcare · NYSE · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

IMPACT BIOMEDICAL INC. (IBO) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores IBO at 33.9/100 on a 32-signal composite quality model, placing it at rank #2,365 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), IMPACT BIOMEDICAL INC. reports quarterly revenue of $3.0K, net income of $-699.0K. Top institutional holders of IBO by reported 13-F value include GEODE CAPITAL MANAGEMENT, VANGUARD CAPITAL MANAGEMENT, STATE STREET, based on the most recent SEC filings. IBO trades on the NYSE exchange and files with the SEC under CIK 1834105. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IBO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for IMPACT BIOMEDICAL INC. directly from SEC EDGAR.